a targeted therapy for myelofibrosis
Published 2 years ago • 223 plays • Length 7:49Download video MP4
Download video MP3
Similar videos
-
7:43
exploring a therapy called jakafi® (ruxolitinib)
-
3:00
ruxolitinib therapy for patients with myelofibrosis
-
5:34
treating with a jak inhibitor for myelofibrosis
-
4:45
myelofibrosis: long-term survival data and ruxolitinib use
-
0:45
exploring fda-approved treatment options for patients with myelofibrosis
-
5:31
case 1: ruxolitinib treatment for myelofibrosis
-
2:03
evaluating prognosis and treatment options for patients with myelofibrosis
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
2:36
case 1: fedratinib treatment for myelofibrosis
-
2:34
early use of jakafi in myelofibrosis beneficial
-
2:10
management of ruxolitinib failure in myelofibrosis
-
1:40
considering fedratinib or ruxolitinib in the frontline setting for treatment of myelofibrosis
-
8:34
what effects has jakafi® (ruxolitinib) shown in clinical trials?
-
1:26
mesa advises community oncologists on jak inhibitors for intermediate-risk myelofibrosis
-
6:23
indications and important safety information for jakafi® (ruxolitinib)
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors
-
7:33
how long should patients take jakafi® (ruxolitinib)?
-
10:01
exploring the possibilities: nick’s journey